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ABSTRACT
Objective To investigate the incidence of new cancer
diagnoses in a community sample of patients with
polymyalgia rheumatica (PMR).
Methods All incident cases of PMR in the UK General
Practice Research Database (GPRD) (1987–99), without
pre-existing cancer or vascular disease and treated with
corticosteroids (n=2877) were matched with up to ﬁve
age, sex and GP practice patients without PMR
(n=9942). Participants were followed up until ﬁrst
cancer diagnosis, death, transfer out of the database or
end of available records.
Results The mean age of the sample was 71.6 years
(SD 9.0), 73% were female. Median follow-up time was
7.8 years (IQR 3.4, 12.3). 667 (23.2%) people with a
PMR diagnosis developed cancer compared with 1938
(19.5%) of those without PMR. There was an interaction
between PMR status and time. In the ﬁrst 6 months
after diagnosis, those with a PMR diagnosis were
signiﬁcantly more likely to receive a cancer diagnosis
(adjusted HR (95% CI): 1.69 (1.18 to 2.42)). The
number of events was small, but occurrences of prostate,
blood, lymph nodes, female reproductive and nervous
system cancers may be more common in those with PMR
in the ﬁrst 6 months after PMR diagnosis.
Conclusions An increase in the rate of cancer
diagnoses was noted in the ﬁrst 6 months of
observation, but we were unable to determine whether
the cancer incidence in PMR was different from controls,
beyond this time point. Clinicians should ensure they
fully exclude cancer as a cause of PMR-like symptoms
and monitor patients for possible malignancies.
INTRODUCTION
With a lifetime prevalence of 2.4% for women and
1.7% for men,1 polymyalgia rheumatica (PMR) is
the commonest inﬂammatory rheumatological
disease in adults aged ≥50 years.2 It is usually diag-
nosed and managed in primary care.3 4 Classic
symptoms are bilateral pain, aching and stiffness in
the shoulders and pelvic girdle, usually accompan-
ied by raised inﬂammatory markers. As the popula-
tion ages,5 the number of cases of PMR is expected
to rise.
It is has been known for some time that
inﬂammatory rheumatological disorders such as
rheumatoid arthritis (RA) and systemic lupus ery-
thematosus (SLE) are associated with increased
rates of certain forms of cancer (RA6 7; SLE8 9).
Despite this, only one large-scale study investigating
the association between PMR and cancer has been
conducted.10 Ji et al10 found a 19% increase in the
risk of cancer in patients admitted to hospital with
PMR and giant cell arteritis (GCA) in Sweden com-
pared with the general population. This association
diminished over time to a 6% increase after the
ﬁrst year. Smaller studies have considered the asso-
ciation of GCA or a combination of PMR and GCA
with cancer in matched prospective cohorts,11–13
but have found no association. To date, however,
no large-scale cohort study has investigated the
potential association between PMR and cancer in
the community, in which the majority of patients
are exclusively diagnosed and managed.3 4
Given the conﬂicting evidence, the true associ-
ation between PMR and cancer in the community
is unclear. This study uses the General Practice
Research Database (GPRD) to prospectively assess
the potential association between PMR and the
subsequent diagnosis of cancer.
METHODS
General Practice Research Database
The GPRD contains the electronic medical records
of patients registered with contributing general
practices in England and Wales. Practices are
broadly representative of all those in England and
Wales for geographical distribution, list size and the
age and sex distribution of registered patients. The
GPRD includes demographic information, prescrip-
tion details, clinical events, preventive care pro-
vided, specialist referrals, hospital admissions and
their major outcomes, coded using the hierarchical
system known as Read codes.14 15 Practices that
contribute to the GPRD must meet strict quality
criteria to provide ‘up-to-standard’ data.16 Recent
reviews conﬁrm the data to be of a good quality
for research,15 although coding was better for
chronic conditions, such as PMR and cancer, than
for acute conditions.17
Participant identiﬁcation
All patients with an incident PMR diagnosis
(a single diagnostic Read code for PMR) between
1 January 1987 and 31 December 1999 were iden-
tiﬁed by GPRD staff and matched with up to ﬁve
individuals without PMR for year of birth, sex and
practice. The index date was taken as the date of
the ﬁrst PMR Read code for those with PMR and
the corresponding matched date for those without.
All participants included were aged ≥50 years at
the index date, had no pre-index record of vascular
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events and had at least 2 years of up-to-standard records before
the index date.
Deﬁnition of cancer
A diagnosis of cancer was identiﬁed using Read codes. The
same deﬁnition of cancer was adopted as that used in a previous
study of cancer in the GPRD18: codes in chapter B (neoplasms),
excluding subchapter B7 (non-malignant neoplasms). Read
codes were converted into GPRD medcodes in order to identify
consultations in the database.
Participant inclusion criteria
To provide further conﬁdence of the accuracy of the PMR diag-
nosis, a method previously used by researchers using the GPRD
was employed.16 Patients with PMR still registered with the
practice 6 months or more after the index date were required to
have at least two prescriptions for oral corticosteroids within
that period. Patients who ceased to be registered with the prac-
tice within 6 months of the index date were required to have
one or more prescriptions for oral corticosteroids between the
index date and the end of their registration. Patients with a
Read-coded diagnosis of PMR but not fulﬁlling these prescrip-
tion criteria were excluded from further analyses. Individuals
without PMR, but who were matched to excluded patients with
PMR, were also excluded. Patients with a diagnosis of cancer
before PMR diagnosis or matched date were excluded. The par-
ticipant selection process is shown in ﬁgure 1.
Outcome measures
The outcome of interest was a diagnosis of cancer. Participants
were followed up to the date of ﬁrst cancer diagnosis, death,
transfer out of the GPRD practice, or until the end of the data
excerpt (latest date May 2011), whichever was the earliest.
Additional risk factors
Smoking status was deﬁned according to the information pro-
vided directly by GPRD. Each person was classiﬁed as ever or
never having smoked.
GPRD medcodes and associated deﬁnitions were used to
deﬁne all other morbidities and are available from the authors,
together with the deﬁnition of an oral steroid.
Statistical analyses
A post hoc power calculation was carried out to determine the
power available in the sample to detect a 20% increased risk of
cancer in the patients with PMR compared with patients
without PMR.
The association between PMR and cancer was investigated
using a Kaplan–Meier plot and was formally quantiﬁed using
Cox proportional hazard models. Follow-up time was divided
into intervals considered to be clinically relevant, (6 months, 1,
2, 5 and 10 years after PMR diagnosis) and a test for interaction
with time performed. Analyses were adjusted for the potential
cofounders of age, sex and smoking status.
Age group (50–59, 60–69, 70–79, ≥80 years), smoking and
sex were also considered potential effect modiﬁers and such an
effect was tested using a Mantel–Haenszel test.
Robust SEs (eg, White19) were used to adjust results for the
matching of those with and without PMR. The proportional
hazards assumption was tested using Schoenfeld residuals.
To investigate whether the types of cancer seen in those with
and without PMR were similar, cancer diagnoses were grouped
according to the anatomical systems affected. The distribution
of these categories in those with and without PMR was then
compared where differences were seen in rates of any cancer.
Analyses were performed using Stata V.12.1and all point esti-
mates were calculated with associated 95% CIs.20
This study received approval from the Independent Scientiﬁc
Advisory Committee for Medicines and Healthcare products
Regulatory Agency database research (protocol number
10_109AR). People are included in an anonymised manner in
the GPRD without explicit informed consent having been
obtained.
RESULTS
A total of 3925 people with a PMR Read code and no pre-
existing vascular disease were identiﬁed. Of these, the diagnosis
Figure 1 Flow chart of participant selection. PMR, polymyalgia rheumatic.
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of PMR could be validated in 3318 individuals who had
received suitable steroid prescriptions and were matched to a
total of 13 016 individuals without PMR (ﬁgure 1). After exclu-
sion of those with a diagnosis of cancer before the date of their
PMR diagnosis, 2877 individuals with a PMR diagnosis and
9942 without PMR were available for analysis.
Assuming a 5% signiﬁcance level and a 20% cancer diagnosis
rate over the course of the study, this sample size gives almost
97% power to detect a HR of 1.2 in a 1 : 4 matched sample.
As would be expected from the matched nature of the design,
those with PMR were of similar age and sex to those without
(table 1), although ever having smoked was more common in
those with PMR (44.1% vs 41.7%).
Over the course of the study the median follow-up time was
7.8 years (IQR 3.4, 12.3). Cancer developed in 667 (23.2%) of
those with PMR and 1938 (19.5%) of those without PMR over
the follow-up period. This association is shown graphically in
ﬁgure 2. There was a signiﬁcant interaction between PMR status
and time, meaning that the association between PMR and
cancer was different in each time period (table 2). There was no
evidence that the association between PMR status and cancer
varied by age group, sex or smoking status. In the ﬁnal model,
residual checks indicated no violation of the assumption of pro-
portional hazards.
Those with PMR were signiﬁcantly more likely to develop
cancer than those without the condition during the ﬁrst
6 months after diagnosis (adjusted HR (95% CI): 1.69 (1.18 to
2.42)) (table 2). After this time, no statistically signiﬁcant associ-
ation was seen and although the CIs were wide, point estimates
were close to the null value of 1.
Owing to small numbers, it is not possible to formally
compare the rates of each type of cancer in the ﬁrst 6 months in
those with and without PMR. However, it appears that there
was an increase in the rates of cancers of the prostate and
lymph nodes (table 3). There is also a suggestion that there may
be higher rates of cancers affecting the blood and female repro-
ductive organs in those with PMR.
DISCUSSION
This study found a 69% increased risk of a cancer diagnosis
within the ﬁrst 6 months after a PMR diagnosis. It could not be
established whether or not the risk in PMR was different from
that of controls, beyond this point. No strong evidence was
found to suggest what types of cancer are seen in patients diag-
nosed with PMR during these 6 months, though data suggested
an excess of cancers of the genitourinary, lymphatic, haemato-
logical and nervous systems.
Prospective studies of the association of PMR and GCA with
cancer are beginning to emerge. The emphasis in these studies is
often on GCA, a condition that overlaps with PMR in about
25% of cases.21 Most of these studies were unable to deﬁnitively
show whether or not there was an association between PMR/
GCA and cancer,11–13 although they have tended to be small
and to focus on patients with GCA. Ji et al10 conducted the
largest study, comparing 36 918 people in Sweden hospitalised
with PMR or GCA with population controls and, as in our
study, found no increased risk of cancer in the long term, but an
excess of cancer diagnoses within the ﬁrst year. Kermani et al11
also found a similar, but non-signiﬁcant, trend suggestive of an
early excess of cancer in patients with a primary diagnosis of
GCA in secondary care.
Our study is the largest community sample to date with anon-
ymised individual patient data available. This allowed those
with PMR to be matched with similar patients without the
disease, more accurately accounting for the potentially con-
founding factors of age and sex than in the Swedish study of
Table 1 Characterises of sample, by PMR exposure status
Characteristic PMR (n=2877) No PMR (n=9942)
Age at index date, mean (SD), years 72.0 (8.9) 71.5 (9.1)
Female, n (%) 2091 (72.7) 7238 (72.8)
Ever smoker, n (%)* 1178 (44.1) 3531 (41.7)
Follow-up time at risk, median (IQR), years 8.4 (3.9, 12.3) 7.6 (3.3, 12.3)
*Contains missing data (10.3%) where smoking status was not recorded in the General
Practice Research Database.
PMR, polymyalgia rheumatica.
Figure 2 Kaplan–Meier plot of the
association between time from
polymyalgia rheumatic (PMR) diagnosis
and diagnosis of cancer. Truncated at
15 years.
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Ji et al.10 It also allowed testing for confounding by smoking
history. However, as with many database studies, we were only
able to consider basic demographic information and speciﬁc
clinical diagnoses entered into the medical record, as more
descriptive information, such as measures of disease activity are
often not recorded.
Although a proportion of those with PMR in this study went
on to develop the related condition of GCA, or other rheumato-
logical conditions such as RA, exclusion of these patients from
the study sample did not change our results.
Other studies have successfully used the GPRD to identify
patients with cancer.18 However, the GPRD comprises data col-
lected in routine practice and can be vulnerable to delays, omis-
sions and miscoding. Such failings, however, are likely to be
similar in both groups in this study. It might be argued that the
inclusion of the need for a corticosteroid prescription in the def-
inition of PMR in this study altered the PMR–cancer associ-
ation, either through masking or accentuating it. However,
reanalysis of the data without this criterion did not alter the
overall ﬁnding of an increase in cancer diagnoses in the early
period after PMR diagnosis and no evidence of a long-term
association. Although a previous study has described an
increased risk of some skin cancers in patients receiving long-
term corticosteroids,22 we think that the increased risk of all
cancers in our study is unlikely to be explained by the use of
steroids, for a number of reasons. First, if steroids were respon-
sible for this increase, it would probably persist beyond
6 months. Second, around a third of individuals in the study of
Sørensen et al20 received stronger corticosteroids (betametha-
sone, triamcinolone) than the prednisolone received in our
study and third, although based on small numbers, our data
suggest that skin cancers occurred at very similar rates in the
ﬁrst 6 months after PMR diagnosis in our study.
The increased rate of cancer within the ﬁrst 6 months after
diagnosis of PMR might occur for several reasons; the most
obvious of which is misdiagnosis. The difﬁculty in diagnosis of
PMR is recognised in recent guidelines from the British Society
for Rheumatology,2 which cite active cancer as a core exclusion
criterion. However, there is some evidence that systemic inﬂam-
mation, as indicated by raised levels of C-reactive protein, may
increase the risk of subsequent colon cancer (eg, Tsilidis et al23),
although evidence for this in other cancers is lacking.24
Furthermore, Ji et al,10 in agreement with our study, noted an
increase in lymphatic and haematopoietic cancers, which might
suggest a dysregulated immune system as a potential common
cause of both PMR and these cancers. However, it seems
unlikely that these biological factors would have such a time-
limited effect. From these data, it is not possible to reach a con-
clusion about why there is an early increase in the diagnosis of
cancer in those with PMR. More data are needed to clearly
Table 2 Association between PMR exposure and all cancer diagnoses, by time period
Cancer diagnoses per 1000 person years HR (95% CI)
PMR No PMR Unadjusted Adjusted*
0–6 months (n=159) 38.9 (29.9 to 50.7) 21.4 (17.6 to 25.9) 1.82 (1.31 to 2.52) 1.69 (1.18 to 2.42)
6–12 months (n=154) 27.9 (20.3 to 38.3) 25.0 (20.8 to 29.3) 1.12 (0.78 to 1.61) 1.03 (0.70 to 1.51)
1–2 years (n=263) 23.6 (18.4 to 30.3) 23.2 (20.2 to 26.6) 1.02 (0.76 to 1.35) 1.04 (0.77 to 1.40)
2–5 years (n=559) 24.6 (21.1 to 28.7) 22.0 (20.6 to 24.5) 1.10 (0.92 to 1.31) 1.04 (0.86 to1.26)
5–10 years (n=866) 29.0 (25.5 to 33.0) 25.2 (23.3 to 27.2) 1.15 (0.99 to 1.34) 1.11 (0.95 to 1.30)
>10 years (n=504) 28.8 (24.1 to 34.4) 27.9 (25.3 to 30.9) 1.03 (0.84 to 1.27) 1.00 (0.82 to 1.23)
*Adjusted for age, gender and smoking status.
PMR, Polymyalgia rheumatica.
Table 3 Rates of cancer diagnosis by anatomical system in the first 6 months after PMR diagnosis
PMR No PMR
Cancer diagnosis n Rate per person-year (95% CI) n Rate per person year (95% CI)
Gastrointestinal 7 0.19 (0.09 to 0.40) 18 0.18 (0.12 to 0.29)
Skin 13 0.15 (0.09 to 0.26) 28 0.13 (0.09 to 0.19)
Prostate 5 0.26 (0.11 to 0.63) 4 0.07 (0.03 to 0.19)
Lung 5 0.28 (0.12 to 0.68) 13 0.28 (.016 to 0.48)
Breast 3 0.13 (0.04 to 0.41) 9 0.10 (0.05 to 0.20)
Female reproductive 3 0.75 (0.24 to 2.34) 7 0.31 (0.15 to 0.64)
Blood 3 0.70 (0.23 to 2.18) 3 0.35 (0.11 to 1.07)
Lymphoma 1 3.32 (0.47 to 24.0) 1 0.09 (0.01 to 0.64)
Urinary tract 3 0.36 (0.12 to 1.12) 4 0.17 (0.07 to 0.46)
Nervous system 2 2.14 (0.54 to 8.57) 0 0.0*
Other† 10 0.36 (0.19 to 0.66) 17 0.36 (0.19 to 0.66)
*CI could not be estimated, as no nervous system cancers were recorded in the non-PMR group.
†Coding did not allow allocation of cancer to a body system. Examples include codes for ‘Cancers’, ‘Malignant neoplasm of other and unspecified site’, ‘Disseminated malignancy not
otherwise specified (NOS)’.
PMR, polymyalgia rheumatica.
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delineate the types of cancer concerned, which might help to
elucidate the reason for this association and lead to improved
management strategies.
In the absence of a ‘gold standard’ diagnostic test and symp-
toms that are often vague and non-speciﬁc, making an accurate
diagnosis of PMR in the community is challenging. Clinicians
need to be aware of the possibility of alternative diagnoses,
including cancer, and carefully monitor those diagnosed with
PMR, especially in the months after the initial diagnosis, for
management and surveillance for the development of cancer.
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